#59773

Date:	**September 17, 2026**
Subject:	**Supernus Pharmaceuticals, Inc. - Anticipated Adjustment** **Option Symbol: SUPN** **New Symbol: SUPN1** **Date: ???**

<u>Contract Adjustment</u>

Date:	Effective the opening of the business day after the merger is consummated. Contract adjustment is anticipated to occur in the fourth quarter of 2026.
Option Symbol:	SUPN changes to SUPN1
Strike Divisor:	1
Contracts Multiplier:	1
New Multiplier:	100 (e.g., a premium of 1.50 yields $150; a strike of 41 yields $4,100.00)
New Deliverable Per Contract:	1) 154 Supernus, Inc. (SUPN) Common Shares 2) Cash in lieu of 0.01 fractional SUPN shares Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.
CUSIP:	(New) SUPN: TBD

<u>Pricing</u>

Until the cash in lieu amount is determined, the underlying price for SUPN1 will be determined as follows:

SUPN1 = 1.5401 (SUPN)

<u>Delayed Settlement</u>

The SUPN component of the SUPN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the SUPN1 deliverable until the cash in lieu of fractional SUPN shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Background

On October 15, 2026, Shareholders of Supernus Pharmaceuticals, Inc. (SUPN) will vote concerning the proposed merger with Indivior Pharmaceuticals, Inc. (INDV). If the merger is approved and consummated, each existing SUPN Common Share will be converted into the right to receive 1.5401 INDV Common Shares. Cash will be paid in lieu of fractional INDV shares.

Following completion of the merger Indivior Pharmaceuticals, Inc. will change its name to Supernus, Inc. and the shares will be traded on Nasdaq under the trading symbol “SUPN”.

Disclaimer

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.